In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

PASI Score

PASI: The gold standard for measuring psoriasis severity and treatment response.

Head (10%)

Area (0-6)Value: 0

erythema

induration

scaling

Trunk (30%)

Area (0-6)Value: 0

erythema

induration

scaling

Upper Limbs (20%)

Area (0-6)Value: 0

erythema

induration

scaling

Lower Limbs (40%)

Area (0-6)Value: 0

erythema

induration

scaling

Calculate Severity

Enter the area, erythema, induration, and scaling for all four body regions to compute the total PASI index.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

The PASI is the gold-standard composite measure of psoriasis severity in clinical trials and a key tool in routine practice for determining eligibility for, and monitoring response to, systemic and biologic therapies. It evaluates both the extent of skin involvement and the intensity of lesional features.

Primary Indications

Assessing severity of chronic plaque psoriasis (psoriasis vulgaris) at baseline

Determining eligibility for biologic therapies (typically requires PASI ≥ 10 with DLQI > 10 per NICE/BAD guidelines)

Monitoring treatment response — tracking PASI 50, PASI 75, PASI 90, and PASI 100 response thresholds

Clinical trial endpoint: virtually all pivotal psoriasis biologic trials use PASI 75 as the primary endpoint

Documenting disease activity for insurance or prior authorization purposes

When NOT to Use

Psoriatic arthritis — PASI captures only skin; use PsARC or DAS28 for joint disease

Pustular or erythrodermic psoriasis — PASI was validated for plaque-type; scores may not reflect clinical severity

Scalp-only or nail-only psoriasis — use Nail Psoriasis Severity Index (NAPSI) or Scalp PGA instead

Routine brief monitoring visits — PASI is time-consuming (5–10 min); IGA is faster for routine use

Pediatric psoriasis — less validated; consider Children's Dermatology Life Quality Index (CDLQI) adjunct

Guideline Threshold

BAD (British Association of Dermatology) and NICE guidelines define severe psoriasis requiring biologic therapy as PASI ≥ 10 AND DLQI > 10, OR PASI ≥ 10 with inadequate response to ≥ 2 conventional systemic therapies.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the DLQI, EASI Score, SCORAD or the IGA to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Dermatology Tools

Melanoma Risk Screening

Lund-Browder Chart

BWH SCC Staging

EASI Score

RegiSCAR DRESS Validation

AJCC Melanoma Staging

Body Surface Area

IGA

MSK Melanoma Nomogram

mPASI

Dermatology Calculators Internal Medicine Calculators Emergency Medicine Calculators

Have feedback about this calculator?Let us know.

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

PASI Score

PASI: The gold standard for measuring psoriasis severity and treatment response.

Head (10%)

Area (0-6)Value: 0

erythema

induration

scaling

Trunk (30%)

Area (0-6)Value: 0

erythema

induration

scaling

Upper Limbs (20%)

Area (0-6)Value: 0

erythema

induration

scaling

Lower Limbs (40%)

Area (0-6)Value: 0

erythema

induration

scaling

Calculate Severity

Enter the area, erythema, induration, and scaling for all four body regions to compute the total PASI index.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Primary Indications

Assessing severity of chronic plaque psoriasis (psoriasis vulgaris) at baseline

Determining eligibility for biologic therapies (typically requires PASI ≥ 10 with DLQI > 10 per NICE/BAD guidelines)

Monitoring treatment response — tracking PASI 50, PASI 75, PASI 90, and PASI 100 response thresholds

Clinical trial endpoint: virtually all pivotal psoriasis biologic trials use PASI 75 as the primary endpoint

Documenting disease activity for insurance or prior authorization purposes

When NOT to Use

Psoriatic arthritis — PASI captures only skin; use PsARC or DAS28 for joint disease

Pustular or erythrodermic psoriasis — PASI was validated for plaque-type; scores may not reflect clinical severity

Scalp-only or nail-only psoriasis — use Nail Psoriasis Severity Index (NAPSI) or Scalp PGA instead

Routine brief monitoring visits — PASI is time-consuming (5–10 min); IGA is faster for routine use

Pediatric psoriasis — less validated; consider Children's Dermatology Life Quality Index (CDLQI) adjunct

Guideline Threshold

Related Scores in Practice

Last Comprehensive Review: 2026

Related Dermatology Tools

Melanoma Risk Screening

Lund-Browder Chart

BWH SCC Staging

EASI Score

RegiSCAR DRESS Validation

AJCC Melanoma Staging

Body Surface Area

IGA

MSK Melanoma Nomogram

mPASI

Dermatology Calculators Internal Medicine Calculators Emergency Medicine Calculators

Have feedback about this calculator?Let us know.